Gender discrepancy in the predictive effect of aortic root diameter on incidence of cardiovascular events among rural Northeast Chinese

Shasha Yu, Xiaofan Guo, Guangxiao Li, Hongmei Yang, Liqiang Zheng, Yingxian Sun

ABSTRACT

Objectives The possible predictive effect of echocardiographic aortic root diameter (ARD) on the incidence of cardiovascular events (CVEs) in a large, general population is limited. In addition, there is a lack of data about rural participants. We intend to figure out the possible relationship between ARD and the incidence of CVEs among the general population from rural China.

Setting Rural areas in Liao Ning Province, Northeast China.

Participants At baseline, 9810 participants (mean age 53±10, 49.1% male) were enrolled in the Northeast China Rural Cardiovascular Health Study between 2012 and 2017.

Main outcome measures Cardiac ultrasonography, lifestyle, medical history, laboratory testing, blood pressure, weight and height. ARD measurement was conducted at the level of the sinuses of Valsalva. Furthermore, the ARD was indexed to height or body surface area.

Results During a median follow-up of 4.66 years, 550 non-fatal or fatal CVEs were recorded. Adjusting for blood pressure, age, total cholesterol, fasting blood glucose, estimated glomerular filtration rate, current smoking and drinking, previous cardiovascular diseases and antihypertensive treatment, ARD/height (HR per 1-unit increase=1.781, 95% CI: 1.160 to 2.736, p=0.008) was associated with an increased risk of CVEs in men only. The combination of left ventricular hypertrophy (LVH) and aortic dilation was an independent and powerful predictor for cardiovascular prognosis compared with aortic dilation alone in men but not in women.

Conclusions Our study enrols a large sample of rural Chinese residents, and first confirms that ARD/height has a predictive effect on the incidence of CVEs among rural Chinese residents. The combination of LVH and aortic dilation is synergistic, which increases its predictive effect on CVEs in men only, suggesting that aortic dilation predicts cardiovascular prognosis better than LVH does in men but not in women.

INTRODUCTION

Aortic dilation has a close relationship with aortic rupture and dissection, which are clinically lethal conditions.1 Previously, it was assumed that aortic root (AR) dilation was prevalent only among patients with Marfan syndrome.2 However, until recently, there is cumulative evidence confirming that, even among patients with only leptosomic features, the rate of aortic dilation is similar to patients with Marfan syndrome.3 In addition, aortic dilation is common among patients with congenital ventricular septal defect, tetralogy of Fallot and chronic kidney disease.4–6 Furthermore, 10 patients with mitochondrial cytopathy also presented with aortic dilation, which had not been previously reported as being associated with mitochondrial disease.7 Aortic extension might be due to cystic medial necrosis. However, the etiology and pathogenesis of this process is complex and still poorly understood. There are some factors that might be responsible for it, such as ageing, hypertension, atherosclerosis, smoking, valvular diseases, trauma, inflammation, family history and specific genetic disorders.8,9 In the Danish Cardiovascular Multicenter Screening Trial, the overall prevalence of ascending aortic dilation was 4.0%, which was close to two times more...

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The present study focuses on the possible predictive effect of aortic root diameter (ARD) in cardiovascular events among rural general Northeast Chinese population in whom no study has been conducted to address these issues.

⇒ The present study did not measure ARD in multiple levels due to the large sample size which might introduce bias.

⇒ The observational design of the present study does not allow for conclusions about the cause of aortic dilation.

⇒ This study used questionnaires to get data from participants; therefore, some data obtained were participants’ subjective perceptions.
than descending aortic dilation. In various types of thoracic aortic dilation, many studies have reported that the most prevalent lesion was ascending aortic dilation. In the Corinthia study, the incidence of AR dilation was 2.4%, and it confirmed the association between alcohol consumption and the incidence of AR dilation.

Left ventricular hypertrophy (LVH) is characterised by an increase in left ventricular (LV) mass, which is due to an increase in wall thickness or LV cavity enlargement or both. There are various clinical conditions that can result in LVH, including essential hypertension, renal artery stenosis, athletic heart with physiological LVH, aortic valve stenosis and coarctation of the aorta. Previous studies have confirmed that LVH is present in 15%–20% of the general population and is more prevalent among blacks, older subjects, the obese and in subjects with hypertension. In addition, there is no significant difference in the prevalence of LVH between men and women. LVH is responsible for causing systolic or diastolic dysfunction and end-stage heart failure. Furthermore, eccentric hypertrophy can significantly increase myocardial oxygen demand, causing angina or ischaemia. A previous study has found that patients with aortic dissection presented with greater LV mass indexes compared with normal subjects and concluded that LV mass is independently associated with the aortic arch, and LVH may be a risk factor for aortic enlargement. Cuspidi and colleagues claimed that aortic root diameter (ARD), in addition to LV mass, could refine cardiovascular risk stratification in the general population.

However, as far as we know, there is a lack of data about ARD and its association with the incidence of cardiovascular events (CVEs) in the general Chinese population, especially in rural areas. In addition, whether there is a synergistic effect of ARD and LVH on prediction of CVEs among the general population remains controversial. Therefore, we aim to evaluate whether the value of ARD is effective in the prediction of the incidence of CVEs in rural Chinese populations, which might help to better understand and control the risk of CVEs; to this purpose, we analysed data obtained in the Northeast China Rural Cardiovascular Health Study (NCRCHS), a population study performed in rural China.

**MATERIALS AND METHODS**

**Study design and participants**

A community-based prospective study named the NCRCHS was carried out in rural China. In brief, we enrolled 11,956 participants (older than 35 years old). The Ethics Committee of China Medical University approved the present study (Shenyang, China AF-SDP-07-1, 0-01).

During 2012–2013, we collected detailed information on the participants, including socioeconomic characters, body circumference measurements, blood pressures and blood tests. In the follow-up study, participants were invited to attend another physical examination during 2015–2017. Among all the participants, 1256 participants were excluded because of lacking contact information, and 86.6% of participants finished at least one follow-up visit, with a median follow-up 4.66 years at the end of the study. Overall, 9,810 out of 10,349 participants who did not have significant cardiac valve disease were enrolled in the present study, including more than one valve with regurgitation, any degree of valvular stenosis or prosthesis.

**Baseline data**

Self-reported history of stroke, coronary heart disease and chronic heart failure at baseline was recorded and confirmed by the medical records. Participants were requested to wear light weight clothing and to take off their shoes when measuring weight and height. Waist circumference was measured as previously described. Obesity was defined using a body mass index (BMI) criteria with the cut-off of ≥28 kg/m² (BMI=weight (kg)/height (m)). Blood pressure measurements followed the standard criteria using an automatic electronic sphygmomanometer (HEM-907; Ommron, Tokyo, Japan). Hypertension was defined as a systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg and/or use of antihypertensive medications. After fasting at least 12 hours, blood samples were collected from participants by trained nurses. Fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC) were analysed enzymatically. We used the Chronic Kidney Disease Epidemiology Collaboration equation to calculate the estimated glomerular filtration rate (eGFR).

**Echocardiography**

Cardiac echocardiography was conducted following standardised procedures. Per the recommendations of the American Society of Echocardiography (ASE), M-mode measurements were performed at the end diastolic and end systolic dimensions. Frames that showed optimal visualisation of interfaces and exhibited simultaneous visualisation of the LV internal diameter, posterior wall and septum were used to calculate. LV mass was estimated by the corrected ASE method and indexed to body surface area (BSA) or height in order to normalise. LVH was defined as a LV mass index equal to or higher than 115 g/m² in men and 99 g/m² in women. At the level of the sinuses of Valsalva, we used M-mode tracings to measure the ARD value, with the maximal distance between the leading edges of the anterior and posterior AR wall at end diastole.
also determined. For all participants reporting possible diagnoses or deaths, all available clinical information was collected, including medical records and death certificates.

The end-point assessment committee was responsible for reviewing and adjusting all materials independently. The WHO Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) criteria was used to define stroke,27 28 as instantly developing signs of global or a focal disturbance of cerebral function, continuing for more than 24 hours (unless interrupted by surgery or death) with no definite non-vascular causes. Stroke cases with a diagnosis of subarachnoid haemorrhage or intracerebral haemorrhage were defined as haemorrhagic stroke, whereas stroke cases with a diagnosis of thrombosis or embolism were defined as ischaemic stroke. Transient ischaemic attacks and chronic cerebral vascular disease were excluded. CHD was defined as a diagnosis of hospitalised angina, hospitalised myocardial infarction, CHD death or any revascularisation procedure.29

Cross-sectional analysis
Sex-specific upper limits of normality (mean±1.96SD) for absolute ARD, index to BSA or height were derived from 931 healthy participants, excluding hypertension, obesity, diabetes, dyslipidaemia and cardiovascular diseases. Values were presented as the means±SDs or as percentages. T-tests, analysis of variance, non-parametric tests or χ²-tests were used to evaluate the differences among categories as appropriate. The strength of linear correlation between variables was tested by Pearson’s correlation coefficient. A multiple linear regression model with stepwise selection was used to identify variables independently associated with the ARD. Clinical variables considered were age, sex, SBP, DBP, serum glucose, TC and TG. Variables were selected by stepwise selection (α=0.05); p values <0.05 were considered statistically significant.

Follow-up analysis
We compared absolute ARD values, ARD/BSA and ARD/height in patients with and without incident CVEs (include non-fatal and fatal cases). HRs of CVEs were evaluated by Cox’s proportional hazard model. HR was calculated per unit increment of ARD (ie, 1 cm, 1 cm/BSA and 1 cm/height). Age, previous cardiac diseases (including angina, myocardial infarction, atrial fibrillation, other kinds of arrhythmia, heart failure and others), antihypertensive treatment, current smoking and drinking, SBP, DBP, TC, FPG and eGFR were all adjusted. Finally, subjects with neither LVH nor AR dilatation (ie, LV mass index <115/99 g/m² and AR <2.4 cm/2.7 cm) were considered to be references, with the rest of the groups including subjects with isolated LVH, isolated AR dilatation or both of these conditions. Kaplan-Meier estimates were adopted to compute the cumulative incidence of CVEs for each group, and the log-rank test was conducted to compare the differences in estimates. SPSS V.17.0 software (Chicago, Illinois, USA) was used to calculate all the statistical analyses, and p values <0.05 were considered to be statistically significant.

Patient and public involvement
There was no patient or public involvement in the design of this study.

RESULTS
Out of the 10349 participants in the present study, 9810 (mean age 53±10 years old, 49.1% male) had echocardiographic data at baseline examination and were used for the present study (table 1).

Normality values of ARD
Sex-specific upper limits of normality (mean±1.96) for absolute ARD, ARD indexed to BSA and to height derived from 931 participants (424 females and 507 males) after excluding participants with hypertension, obesity, diabetes, dyslipidaemia and cardiovascular diseases were the following: 2.40 cm, 1.66 cm/m², and 1.53 cm/m, respectively, in women and 2.70 cm, 1.71 cm/m², and 1.66 cm/m, respectively, in men. According to these values, the prevalence of aortic dilatation in the whole study sample (n=9810) varied from 4.2% (ARD/BSA) to 13.3% (ARD). Women had a significantly higher rate of aortic dilatation compared with men (ARD/BSA: 5.1% vs 3.1%; ARD: 15.1% vs 11.1%; ARD/height: 13.5% vs 6.0%, all p<0.001).

Table 2 shows data about the absolute ARD, ARD/BSA and ARD/height in participants with or without metabolic disorders. The values of ARD and ARD/height increased with elevated WC and TG in both sexes whereas ARD/BSA decreased. Similarly, ARD and ARD/height were higher among the impaired fasting glucose and high LDL groups in both women and men, while ARD/BSA decreased in men but not in women. ARD/BSA significantly decreased with high TC among men and women. With regard to low HDL-C, men had higher ARD and lower ARD/BSA values, whereas women had lower ARD/BSA values only.

Correlation analyses
Table 3 shows that absolute ARD was positively correlated with all indexes while ARD/BSA did not correlate with heart rate, LDL-C and FPG. ARD/height did not correlate with heart rate only among women. Among men, absolute and indexed ARD values were not correlated with heart rate. In addition, ARD did not correlate with TC, LDL-C and eGFR, while ARD/BSA did not correlate with LV mass. ARD/height did not correlate with TC, HDL-C and uric acid (UA). After multiple regression analyses, age, BMI, mean DBP, heart rate, FPG and LV mass/BSA were still significantly associated with absolute ARD among women, whereas among men, age, BMI, mean DBP, TC, LV mass/BSA, TG and HDL-C were still significantly associated. Age, LV mass/BSA, BMI, and eGFR were
predictors of ARD/BSA among women, while age, BMI, mean SBP, LV mass/BSA, eGFR and HDL-C were predictors among men. Age, BMI, heart rate and LV mass/BSA were the predictors of ARD/height among women, while age, BMI, mean SBP, TC, LV mass/BSA, TG, eGFR and HDL-C were the predictors among men. Interestingly, in all models, LV mass/BSA was the most important factor independently associated with ARD, ARD/BSA and ARD/height after age and body size measurements. Table 4 shows the multivariate analysis between ARD parameters and different variables. Sex, age and BMI were significantly associated with all ARD parameters. In general subjects, DBP, heart rate, TG, HDL-C, FPG, UA, relative wall thickness and LV mass were significantly associated with ARD. Similarly, there were apparent associations between SBP, HDL-C, eGFR, LV mass and ARD/height after age and body size measurements.

Table 1  Clinical characteristics of the subjects at the baseline

| Variables               | Women (n=5286) | Men (n=4524) | Total (n=9810) |
|-------------------------|----------------|--------------|----------------|
| Age (years)             | 53.31±10.23    | 54.14±10.63  | 53.69±10.42    |
| BMI (kg/m²)             | 24.89±3.84     | 24.77±3.51   | 24.83±3.69     |
| BSA (m²)                | 1.57±0.15      | 1.74±0.16    | 1.65±0.18      |
| WC (cm)                 | 81.06±9.76     | 83.72±9.65   | 82.29±9.80     |
| Height (m)              | 1.56±0.06      | 1.66±0.06    | 1.61±0.08      |
| SBP (mm Hg)             | 140.37±24.01   | 143.87±22.46 | 141.98±23.37   |
| DBP (mm Hg)             | 80.62±11.44    | 83.90±11.77  | 82.14±11.71    |
| Heart rate (bpm)        | 79.98±13.10    | 76.41±13.06  | 78.33±13.20    |
| TC (mmol/L)             | 5.31±1.13      | 5.19±1.04    | 5.25±1.09      |
| TG (mmol/L)             | 1.58±1.28      | 1.63±1.62    | 1.60±1.44      |
| LDL-C (mmol/L)          | 2.99±0.86      | 2.91±0.81    | 2.96±0.83      |
| HDL-C (mmol/L)          | 1.42±0.35      | 1.42±0.39    | 1.42±0.39      |
| FPG (mmol/L)            | 5.86±1.58      | 5.94±1.64    | 5.89±1.61      |
| UA (mmol/L)             | 252.67±66.68   | 330.15±80.96 | 288.32±83.11   |
| eGFR (mi/min/1.73 m²)   | 92.68±16.05    | 94.64±14.49  | 93.58±15.38    |
| ARD (cm)                | 2.14±0.32      | 2.37±0.28    | 2.25±0.32      |
| ARD/BSA (cm/m²)         | 1.37±0.22      | 1.37±0.19    | 1.37±0.21      |
| ARD/height (cm/m)       | 1.38±0.21      | 1.42±0.17    | 1.40±0.20      |
| RWT                     | 0.38±0.25      | 0.38±0.25    | 0.38±0.25      |
| LV mass (g)             | 125.15±37.95   | 154.88±42.56 | 138.86±42.79   |
| LV mass/BSA (g/m²)      | 79.91±23.09    | 89.09±23.53  | 84.14±23.73    |
| LV mass/height (~ g/m²) | 38.19±12.15    | 39.38±11.56  | 38.74±11.90    |
| IVSTD (cm)              | 0.85±0.13      | 0.91±0.16    | 0.88±0.15      |
| LVPWTD (cm)             | 0.84±0.22      | 0.89±0.15    | 0.86±0.19      |
| LVEDD (cm)              | 4.54±0.41      | 4.90±0.43    | 4.70±0.46      |
| EF (%)                  | 62.70±3.84     | 62.93±3.89   | 62.81±3.87     |
| Antihypertensive drugs (%) | 892 (70.5)    | 550 (63.5)   | 1442 (67.6)    |
| Previous CV events (%)  | 1059 (20.0)    | 500 (11.1)   | 1559 (15.9)    |
| Current smoking (%)     | 858 (16.2)     | 2620 (57.9)* | 3478 (35.5)    |
| Current drinking (%)    | 153 (2.9)      | 2066 (45.7)* | 2219 (22.6)    |
| Diabetes (%)            | 616 (11.7)     | 479 (10.6)   | 1095 (11.2)    |
| Dyslipidaemia (%)        | 4255 (80.5)    | 3198 (70.7)* | 7453 (76.0)    |

Data are shown as means±SD, percentages or absolute numbers. RWT was defined by the ratio of posterior wall and IVS thickness to LVIDd. *P<0.05 versus women. ARD, aortic root diameter; BSA, body surface area; DBP, diastolic blood pressure; EF, ejection fraction; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; IVSTD, interventricular septum thickness in diastole; LDL-C, low-density lipoprotein cholesterol; LVIDd, left ventricular end-diastolic diameter; LVIDd, left ventricular internal diameter in diastole; LVFWTD, left ventricular posterior wall thickness in diastole; RWT, relative wall thickness; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid; WC, Waist circumference.
In addition, HDL-C, eGFR and LV mass significantly correlated with ARD/height in the general population. Furthermore, sex discrepancies existed in these associations, which are also shown in table 4.

**Prognostic significance of baseline ARD**

A total of 550 CVEs (non-fatal or fatal) were recorded (203 coronary heart diseases, 83 myocardial infarctions and 365 strokes). Out of the 550 events, 73 due to coronary heart diseases, 54 due to myocardial infarction and 120 due to strokes were fatal (44.9%). The first event for every participant was considered in the counting of total events.

The association between the ARD at the baseline evaluation and incidence of CVEs was investigated by comparing ARD values in subjects with and without incident CVEs; by calculating the risk of CVEs related per 1-unit increase in ARD in both unadjusted and adjusted Cox models; and by assessing the risk of CVEs in subjects divided into four groups: LVH (−) and ARD (−) (reference group), LVH (+) and ARD (−), LVH (−) and ARD (+), and LVH (+) and ARD (+).

| Women | Men |
|-------|-----|
| Normal BP | High BP | P value | Normal BP | High BP | P value |
| ARD | 2.11±0.30 | 2.18±0.33 | <0.001 | 2.33±0.26 | 2.40±0.29 | <0.001 |
| ARD/height | 1.35±0.20 | 1.41±0.22 | <0.001 | 1.40±0.16 | 1.45±0.18 | <0.001 |
| ARD/BSA | 1.37±0.22 | 1.38±0.23 | 0.003 | 1.36±0.17 | 1.38±0.20 | 0.004 |

| Normal WC | Elevated WC | P value | Normal WC | Elevated WC | P value |
|-----------|-------------|--------|-----------|-------------|--------|
| ARD | 2.09±0.34 | 2.18±0.29 | <0.001 | 2.34±0.29 | 2.43±0.26 | <0.001 |
| ARD/height | 1.35±0.23 | 1.40±0.19 | <0.001 | 1.41±0.18 | 1.45±0.16 | <0.001 |
| ARD/BSA | 1.42±0.25 | 1.34±0.20 | <0.001 | 1.40±0.19 | 1.29±0.15 | <0.001 |

| Normal FPG | IFG | P value | Normal FPG | IFG | P value |
|-----------|-----|--------|-----------|-----|--------|
| ARD | 2.13±0.32 | 2.15±0.31 | 0.006 | 2.36±0.26 | 2.38±0.30 | 0.027 |
| ARD/height | 1.37±0.21 | 1.39±0.21 | <0.001 | 1.42±0.16 | 1.43±0.18 | 0.033 |
| ARD/BSA | 1.38±0.23 | 1.37±0.22 | 0.685 | 1.37±0.18 | 1.36±0.20 | 0.048 |

| Normal HDL | Low HDL-C | P value | Normal HDL | Low HDL-C | P value |
|-----------|----------|--------|-----------|----------|--------|
| ARD | 2.13±0.32 | 2.15±0.31 | 0.071 | 2.36±0.29 | 2.39±0.26 | 0.022 |
| ARD/height | 1.38±0.21 | 1.38±0.21 | 0.447 | 1.42±0.18 | 1.43±0.16 | 0.258 |
| ARD/BSA | 1.39±0.23 | 1.35±0.21 | <0.001 | 1.38±0.19 | 1.33±0.17 | <0.001 |

| Normal TG | Hypertriglycerides | P value | Normal TG | Hypertriglycerides | P value |
|-----------|-------------------|--------|-----------|-------------------|--------|
| ARD | 2.12±0.29 | 2.18±0.37 | <0.001 | 2.35±0.30 | 2.40±0.25 | <0.001 |
| ARD/height | 1.37±0.19 | 1.40±0.25 | <0.001 | 1.42±0.18 | 1.44±0.15 | 0.001 |
| ARD/BSA | 1.38±0.21 | 1.36±0.26 | 0.030 | 1.38±0.20 | 1.33±0.16 | <0.001 |

| Normal TC | High TC | P value | Normal TC | High TC | P value |
|-----------|--------|--------|-----------|--------|--------|
| ARD | 2.37±0.27 | 2.37±0.29 | 0.677 | 2.37±0.27 | 2.37±0.29 | 0.677 |
| ARD/height | 1.42±0.17 | 1.43±0.18 | 0.499 | 1.42±0.17 | 1.43±0.18 | 0.499 |
| ARD/BSA | 1.38±0.17 | 1.36±0.19 | 0.010 | 1.38±0.19 | 1.36±0.19 | 0.010 |

| Normal LDL | High LDL-C | P value | Normal LDL | High LDL-C | P value |
|-----------|----------|--------|-----------|----------|--------|
| ARD | 2.13±0.29 | 2.16±0.36 | 0.005 | 2.36±0.26 | 2.38±0.32 | 0.008 |
| ARD/height | 1.37±0.19 | 1.40±0.24 | <0.001 | 1.42±0.16 | 1.44±0.19 | 0.003 |
| ARD/BSA | 1.37±0.21 | 1.38±0.25 | 0.612 | 1.37±0.18 | 1.35±0.20 | <0.001 |

Data are shown as means±SD.
ARD, aortic root diameter; BP, blood pressure; BSA, body surface area; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.
Table 3  Correlation between ARD parameters and metabolic variables

|                  | ARD (cm)   | ARD/BSA (cm/m²) | ARD/height (cm/m) |
|------------------|-----------|-----------------|-------------------|
|                  | Women     | Men             | Women            | Men            | Women | Men             | Women  | Men             |
|                  | r         | P value         | r                | P value        | r     | P value         | r     | P value         |
| Age (years)      | 0.136     | <0.001          | 0.061            | <0.001         | 0.280 | <0.001          | 0.269  | <0.001          | 0.244 | <0.001          | 0.160  | <0.001          |
| BMI (kg/m²)      | 0.248     | <0.001          | 0.201            | <0.001         | -0.365 | <0.001          | -0.387 | <0.001          | 0.247 | <0.001          | 0.190  | <0.001          |
| SBP (mm Hg)      | 0.150     | <0.001          | 0.156            | <0.001         | 0.044  | 0.002           | 0.057  | <0.001          | 0.204 | <0.001          | 0.184  | <0.001          |
| DBP (mm Hg)      | 0.120     | <0.001          | 0.131            | <0.001         | -0.048 | <0.001          | -0.036 | 0.016           | 0.125 | <0.001          | 0.117  | <0.001          |
| Heart rate (bpm) | -0.050    | <0.001          | -0.014           | 0.362          | 0.024  | 0.075           | 0.007  | 0.655           | -0.016 | 0.234           | -0.001 | 0.921          |
| TC (mmol/L)      | 0.053     | <0.001          | -0.001           | 0.945          | 0.041  | 0.003           | -0.050 | 0.001           | 0.100 | <0.001          | 0.011  | 0.463           |
| TG (mmol/L)      | 0.108     | <0.001          | 0.091            | <0.001         | -0.050 | <0.001          | -0.155 | <0.001          | 0.131 | <0.001          | 0.067  | <0.001          |
| LDL-C (mmol/L)   | 0.047     | 0.001           | 0.028            | 0.063          | -0.020 | 0.147           | -0.096 | <0.001          | 0.090 | <0.001          | 0.038  | 0.012           |
| HDL-C (mmol/L)   | -0.071    | <0.001          | -0.041           | 0.006          | 0.101  | <0.001          | 0.178  | <0.001          | -0.044 | 0.002           | -0.007 | 0.633           |
| FPG (mmol/L)     | 0.080     | <0.001          | 0.046            | 0.002          | -0.009 | 0.527           | -0.037 | 0.012           | 0.096 | <0.001          | 0.051  | 0.001           |
| UA (mmol/L)      | 0.119     | <0.001          | 0.050            | 0.001          | -0.035 | 0.012           | -0.153 | <0.001          | 0.118 | <0.001          | 0.005  | 0.716           |
| eGFR (mi/min/1.73m²) | -0.094 | <0.001          | -0.004           | 0.781          | -0.146 | <0.001          | -0.046 | 0.002           | -0.125 | <0.001          | -0.041 | 0.007           |
| RWT              | 0.067     | <0.001          | 0.036            | 0.014          | 0.105  | <0.001          | 0.064  | <0.001          | 0.124 | <0.001          | 0.077  | <0.001          |
| LV mass (g)      | 0.291     | <0.001          | 0.273            | <0.001         | -0.042 | 0.002           | -0.017 | 0.251           | 0.256 | <0.001          | 0.233  | <0.001          |
| LV mass/BSA (g/m²) | 0.194 | <0.001          | 0.189            | <0.001         | 0.210  | <0.001          | 0.219  | <0.001          | 0.266 | <0.001          | 0.250  | <0.001          |
| LV mass/height².7 (g/m²²) | 0.228 | <0.001          | 0.239            | <0.001         | 0.140  | <0.001          | 0.151  | <0.001          | 0.356 | <0.001          | 0.318  | <0.001          |

ARD, aortic root diameter; BMI, body mass index; BP, blood pressure; BSA, body surface area; DBP, diastolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; RWT, relative wall thickness; SBP, systolic blood pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid.
Table 4 Multivariate analysis between ARD parameters and different variables

|                  | ARD (cm)   | ARD/BSA (cm/m²) | ARD/height (cm/m) |
|------------------|------------|-----------------|------------------|
|                  | Total Women Men | Total Women Men | Total Women Men |
| Gender           | 0.272      | −0.058          | 0.063            |
| Age (years)      | 0.075      | 0.090           | 0.075            |
| BMI (kg/m²)      | 0.103      | 0.122           | 0.098            |
| SBP (mm Hg)      | −0.004     | −0.025          | 0.029            |
| DBP (mm Hg)      | 0.042      | 0.046           | 0.038            |
| Heart rate (bpm) | −0.041     | −0.066          | −0.011           |
| TC (mmol/L)      | −0.063     | −0.021          | −0.135           |
| TG (mmol/L)      | 0.038      | 0.009           | 0.078            |
| LDL-C (mmol/L)   | 0.024      | −0.007          | 0.074            |
| HDL-C (mmol/L)   | 0.037      | 0.016           | 0.067            |
| FPG (mmol/L)     | 0.026      | 0.032           | 0.019            |
| UA (mmol/L)      | 0.024      | 0.023           | 0.020            |
| eGFR (mi/min/1.73 m²) | 0.018     | 0.005           | 0.049            |
| RWT              | −0.021     | −0.009          | −0.036           |
| LV mass (g)      | 0.142      | 0.108           | 0.181            |

Table 5 Relative hazard rates relating increments of one unit measurement of ARD parameters to the incidence of cardiovascular events

|                  | Women | Men |
|------------------|-------|-----|
|                  | HR 95% CI | P value | HR 95% CI | P value |
| Model 1 ARD (cm) | 1.237 0.935 1.637 | 0.137 | 1.575 1.228 2.019 | <0.001 |
| Model 2 ARD (cm) | 0.991 0.950 1.033 | 0.991 | 1.330 0.966 1.832 | 0.081 |
| Model 1 ARD/BSA (cm/m²) | 1.558 1.099 2.209 | 0.013 | 2.202 1.549 3.128 | <0.001 |
| Model 2 ARD/BSA (cm/m²) | 1.066 0.538 2.106 | 0.824 | 1.502 0.966 2.336 | 0.071 |
| Model 1 ARD/height (cm/m) | 1.597 1.124 2.270 | 0.009 | 2.603 1.876 3.612 | <0.001 |
| Model 2 ARD/height (cm/m) | 0.980 0.454 2.113 | 0.980 | 1.781 1.160 2.736 | 0.008 |

ARD, aortic root diameter; ARD/BSA, aortic root diameter to body surface area; ARD/height, aortic root diameter to height; BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; RWT, relative wall thickness; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid.

p=0.001; ARD/BSA=1.37±0.18 cm/m², p<0.001; ARD/height=1.42±0.17 cm/m, p<0.001).

Table 5 shows relative HRs for the risk of CVEs associated with per 1-unit increase in absolute ARD, ARD/BSA and ARD/height. After adjusting for age, previous cardiac diseases, antihypertensive treatment, current smoking and drinking, SBP, DBP, TC, FPG, eGFR, ARD/height (HR: 1.781, 95% CI: 1.160 to 2.736, p=0.008) predicted an increased risk of CVEs among men but not among women.

Figure 1 reports the incidence rates of CVEs in subjects divided into four groups according to the status of LVH and AR dilatation. After full adjustment, men with AR dilatation and without LVH were significantly higher than those without AR dilatation or LVH (reference group) (HR: 1.487, 95% CI: 1.000 to 2.212, p=0.050). Furthermore, compared with the reference group, the adjusted risk of subjects with LVH and AR dilatation was even higher than those with isolated AR dilatation (HR: 1.950, 95% CI: 1.168 to 3.256, p=0.011), while among women, LVH but not AR dilatation was associated with a higher incidence of CVEs. Figure 2 is the Kaplan-Meier cardio-vascular disease survival curves for the four groups among men and women. Kaplan-Meier analysis showed that there were significant differences in the survival rates among these groups (log-rank testing, p<0.01) in both women and men.
and men. Among women, log-rank testing showed that the survival rate was significantly lower in the LVH (+) and ARD (−) group (p<0.01) and LVH (+) and ARD (+) group (p<0.01) compared with the LVH (−) and ARD (−) group. There were no significant differences between the LVH (−) and ARD (+) and LVH (−) and ARD (−) groups (p=0.278). For men, when compared with the LVH (−) and ARD (−) group, the other three groups all showed a significant decrease survival rates (all p<0.05).

**DISCUSSION**

The present study enrolled a large sample from the general population of rural China and for the first time, reported the existence of sex discrepancies with regard to the predictive effect of ARD and its indexes of the incidence of cardiovascular diseases. It showed that ARD/height (but not ARD and ARD/BSA) was associated with the incidence of non-fatal and fatal CVEs among rural Chinese men only. After adjusting for possible confounders, ARD indexed to height was a significant predictor of incident CVEs. It is worth noting that AR dilation (but not LVH) was significantly correlated with CVEs among rural Chinese men, whereas LVH was associated with a higher rate of CVEs among women. However, the combination of LVH and AR dilation was a stronger predictor of cardiovascular outcomes than that entailed by LVH or AR dilation alone among men.

The evaluation of aortic diameters has great effect on the clinical estimation and management of diseases of the aorta. However, until recently, there was still a lack of normal range of aortic diameters in the general population due to the different measurement sites, race and composition of analysed studies. Vriz et al conducted a study aiming to figure out the average value of ARD in a wide age range of healthy subjects. It reported that men had a significantly higher value of ARD compared...
with women in all age groups, and as age increased, the average value of ARD increased in both men and women. In addition, it concluded that blood pressure had a close relationship with ARD. In our study, except for blood pressure, we evaluated many other metabolic disorders aiming to figure out the possible association between them. Data from our study revealed that ARD was relatively higher in abnormal metabolic disorders, except in high TC among both sexes and low HDL-C among women. It suggested the possibility that, in addition to hypertension, other metabolic disorders might play a role in altering ARD. We further explored the possible relationship between ARD, ARD indexes and other metabolic parameters, such as blood pressure, lipids, glucose, UA and kidney function. We figured out that ARD was associated with all the parameters studied among women but not TC, LDL-C and kidney function among men.

Cumulative evidence indicated the importance of ARD on cardiovascular diseases. Recently, Katchunga reported the prevalence of AR dilatation was 3.5% among Congolese and confirmed that ARD had a close relationship with LV mass, LV diastolic diameter and E/A ratio. Similarly, Anders Sahlin claimed that larger AR size was an independent determinant of lower global afterload and larger stroke volume. One review enrolled a total of eight studies including 10791 patients with hypertension and concluded that aortic dilatation was a common phenotype in patients with hypertension (total: 9.1%; 12.7% for men; 4.5% for women), with men exhibiting a markedly higher susceptibility. However, in our study, the rate of aortic dilatation was higher in women compared with men. It might be due to the difference in the selection of participants. In our study, we enrolled the general population rather than patients with hypertension. There were also many previous studies that have confirmed the predictive effect of ARD on CVEs. In the Cardiovascular Health Study, which enrolled 3995 elderly without cardiovascular diseases at baseline, the ARD at baseline had a significant relationship with a higher incidence of stroke and cardiovascular mortality over one decade of follow-up. Likewise, in our study, we found that ARD/height was an effective predictor of the onset of CVEs. Most of the previous studies which intended to estimate the possible predictive effect of ARD on CVEs or CV mortality enrolled only elderly or middle-aged general population. As for our study, our contribution extends to an aged ≥35 years general population sample. Previous studies held the conclusion that echocardiographic assessment of ARD may contribute to stratify the risk of CVEs in elderly or middle-aged participants who suffered from greater likelihood of aortic dilatation due to age-dependent underlying structural changes in the aortic wall. Nevertheless, our study added a new prospect that echocardiographic assessment of ARD can be used to assess the stratification of CVEs in younger healthy individuals from the general population equally. Besides, a novel contribution of the present study is that ARD/height but not absolute ARD and ARD/BSA was effective predictor of CVEs among male but not female. This gender discrepancy of ARD predicting CVEs was not mentioned previously. This emphasises that ARD index to height was a significant predictor of CVEs among rural male residents. Hence, a relatively more frequent follow-up should be recommended by physician once rural male residents were diagnosed with ARD. As we evaluate the cardiovascular risk factors, increased ARD index to height should be considered as well. However, this gender discrepancy was also coincident with the previous study, which enrolled subjects with hypertension, claiming that men had a markedly higher susceptibility. Why ARD was predictive of CVEs in men but not in women is not known. There were some possible factors that might be relevant about this phenomenon. First, as previously reported, aortic remodelling increases with increasing age and aged-associated advancement of ARD is well-established in epidemiological studies. As shown in our study, the mean age in men was significantly higher than that of women, resulting in relatively higher value of ARD in men. Second, many previous studies have found that men had a significantly larger ARD compared with women, regardless of age, race or which body size adjustment was used. The larger value of ARD in men might result in a more significant relationship between ARD value and CVEs while estimating. Third, the Cardiovascular Health Study also reported that the highest quintile of ARD was found to be a significant but modest predictor of congestive heart failure with LV systolic dysfunction in men (overall HR 1.47) but not in women. They considered that this might be due to the relatively higher prevalence of CHF with LV systolic dysfunction among men. Similarly, in our study, ARD being able to predict CVEs among men but not among women might be associated with the relatively lower risk for cardiovascular diseases among women in general. Therefore, it suggested that more emphasis should be put on rural Chinese men who have a relatively higher value of ARD or aortic dilatation.

Except for aortic dilatation, there are many cardiac ultrasound indexes related to cardiovascular diseases, such as LVMI (left ventricular mass index), which is used to estimate LVH. It is very clear that both greater LVMI and LV concentric or eccentric hypertrophy are associated with higher mortality and adverse cardiovascular disease outcome. Many previous studies found out an independent association of increased LV mass with aortic dilatation in different clinical settings, like patients with hypertension, patients with acute thoracic dissection and elderly individuals. The Framingham Heart Study reported that as a continuous variable, the predictive value of ARD lost its statistical significance as LV mass index was adjusted in the multivariable model. However, if subjects were subdivided into four groups according to the presence/absence of LVH or AR dilatation, the fully adjusted risk of CVEs was markedly greater in those combination of LVH and aortic dilatation compared with their counterparts with LVH alone. In order to further confirm this association among rural Chinese, we further...

Yu S, et al. BMJ Open 2022;12:e039207. doi:10.1136/bmjopen-2020-039207
ran this analysis and added a new piece of information over previous evidence by revealing that the overall risk is significantly increased when residents have both LV structure alterations together with aortic dilatation as compared with isolated alterations of LV structure. In addition, our study first time announced that the combination predictive effect of LVH and aortic dilatation on CVEs was only significant among men but not women rural residents. More emphasis should be put on men who have both LVH and aortic dilatation since they had significantly higher risk factors to get CVEs.

There have already been many studies intended to estimate the relationship between ARD, cardiovascular diseases and risk factors. The results from the Framingham Heart Study claimed that, after adjustment for clinical risk factors, a greater ARD at baseline, as well as an increase in ARD over 8 years, was correlated with the risk of incident heart failure. However, after adjustment for LVM, this association was no longer significant. In the Jackson Heart Study, which enrolled only blacks, reported that a greater ARD increased the risk of CVEs in a community-based cohort of blacks. Similarly, in our study, we confirmed that ARD and its index was significantly associated with CVEs in men, whereas after adjustment of BMI, only ARD/height was still effective in predicting CVEs. The greater difference between our study and the Framingham Heart Study was that the previous study only estimated the incidence of heart failure. Both of the previous two studies did not underestimate this relationship according to sex. Furthermore, they only estimated the predictive effect of ARD but no other ARD-related indexes, which might also be effective parameters in predicting cardiovascular diseases and risk factors.

There are some limitations of the present study. First, due to the large sample, we did not measure ARD in multiple levels, such as the annulus, supra-aortic ridge and ascending aorta, which might have introduced bias. The observational design of the present study does not allow for conclusions about the cause of aortic dilatation. In addition, the association between ARD and metabolic disorders, such as dyslipidaemia, high fasting glucose and kidney function, was based on a single blood test that might have bias. Furthermore, a low incidence of cardiovascular events (<10% over a 4.66-year follow-up period) was observed among rural Northeast China which might explain the limited strength of correlation between ARD and CVEs.

CONCLUSIONS
The present study enrolled a large study sample of general rural residents in China and for the first time, presented that sex discrepancies existed in the association between ARD, ARD indexes and future risk of CVEs. Among rural Chinese men, ARD plays an important role in predicting subclinical organ damage for better assessing prognosis and prevention strategies. In addition, the combination of LVH and aortic dilatation in our study presented a stronger predictive effect on cardiovascular outcomes than aortic dilatation alone.

REFERENCES
1 Erbel R, Aboyans V, Boileau C. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult, the task force for the diagnosis and treatment of aortic diseases of the European Society of cardiology (ESC). Eur Heart J 2014;35:2873–926.
2 Loeyls BL, Dietz HC, Braverman AC, et al. The revised ghtenosology for the marfan syndrome. J Med Genet 2010;47:476–85.
3 Brozovich FV. Aortic root dilation in patients with leptosomia features. Mayo Clin Proc 2018;93:136–7.
4 Briet M, Bozec E, Laurent S, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006;69:350–7.
5 Seko M, Kuwata S, Kurishima C, et al. Mechanism of aortic root dilation and cardiovascular function in tetralogy of fallot. Pediatr Int 2016;58:323–30.
6 Li H-Y, Zhao Y-F, Dai L, et al. Ascending aortic dilation in adult patients with congenital ventricular septal defect: an observational study. Medicine 2018;97:e0383.
7 Brunetti-Pierri N, Pignatti R, Fouladi N, et al. Dilation of the aortic root in mitochondrial disease patients. Mol Genet Metab 2011;103:167–70.
8 Miikowicz Dawid L, Lipiec P, Kasprzak JD, Bicusp it aortic valve morphology and its association with aortic diameter: an echocardiographic study. Kardiol Pol 2016;74:151–8.
9 Miikowicz D, Lipiec P, Szymczyk E, et al. Bicuspid aortic valve morphology and its impact on aortic diameters: a systematic review with meta-analysis and meta-regression. Echocardiography 2018;35:667–77.
10 Wild JB, Stather PW, Bianari F, et al. A multicentre observational study of the outcomes of screening detected sub-aneurysmal aortic dilatation. Eur J Vasc Endovasc Surg 2013;45:129–34.
11 Guo D-C, Papke CL, He R, et al. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci 2006;1085:339–52.
12 Oikonomou E, Lazaros G, Tsalamandris S, et al. Alcohol consumption and aortic root dilatation: insights from the corinthia study. Angiology 2019;70:969–77.
13 Bornstein AB, Rao SS, Marwaha K. Left ventricular hypertrophy (LVH). StatPearls. treasure island (FL). StatPearls Publishing, 2020.
Echocardiogr 2010;11:645–58.

30. Evangelista A, Flachskampf FA, Erbel R, et al. Echocardiography in aortic disease: EAE recommendations for clinical practice. Eur J Echocardiogr 2010;11:645–58.

31. Vriz O, Driussi C, Bettio M, et al. Aortic root dimensions and stiffness in healthy subjects. Am J Cardiol 2013;112:1224–9.

32. Katchunga P, Kaishusha D, Mwambusa R, et al. [Prevalence of the proximal aortic root dilatation and it relationship with left ventricular remodelling among South-Kivu congolese patients: a cross sectional study]. J Am Coll Cardiol 2016;116:1355–65.

33. Sahtian A, Hamid N, Amanullah MR, et al. Impact of aortic root size on left ventricular afterload and stroke volume. Eur J Appl Physiol 2016;116:1355–65.

34. Covella M, Milan A, Totaro S, et al. Echocardiographic aortic root dilatation in hypertensive patients: a systematic review and meta-analysis. J Hypertens 2014;32:1928–35.

35. Gardin JM, Arnold AM, Polak J, et al. Usefulness of aortic root dimension in persons > or = 65 years of age in predicting heart failure, stroke, cardiovascular mortality, all-cause mortality and acute myocardial infarction (from the cardiovascular health study). Am J Cardiol 2006;97:270–5.

36. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003;107:139–46.

37. Vasan RS, Larson MG, Levy D. Determinants of echocardiographic aortic root size, the framingham heart study. Circulation 1995;91:734–40.

38. Segers P, Rietzschel ER, De Buyzere ML, et al. Noninvasive (input) impedance, pulse wave velocity, and wave reflection in healthy middle-aged men and women. Hypertension 2007;49:1248–55.

39. Lam CSF, Gona P, Larson MG, et al. Aortic root remodelling and risk of heart failure in the framingham heart study. JACC Heart Fail 2013;1:79–83.

40. Gerds T, Izzi R, Mansuci C, et al. Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the campania salute network). Int J Cardiol 2018;258:257–61.

41. Tsao CW, Gona PN, Salton CJ, et al. Left ventricular structure and risk of cardiovascular events: a framingham heart study cardiac magnetic resonance study. J Am Heart Assoc 2015;4:e002188.

42. Teh RO, M Kerse N, M Robinson E, et al. Left ventricular geometry and all-cause mortality in advanced age. Heart Lung Circ 2015;24:32–9.

43. Bella JN, Wachtell K, Boman K, et al. Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the life study). Am J Cardiol 2002;89:337–41.

44. Kamimura D, Suzuki T, Musani SK, et al. Increased proximal aortic diameter is associated with risk of cardiovascular events and all-cause mortality in blacks the Jackson heart study. J Am Heart Assoc 2017;6. doi:10.1161/JAHA.116.005005. [Epub ahead of print: 21 Jun 2017].